GlassScriptPhysician profile
Raju Patnam
NPI 1407817844
$1,052.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.58 | 2019 | |
| Amgen INC. | $181.17 | 2019 | |
| Glaxosmithkline, LLC. | $121.64 | 2019 | |
| Astellas Pharma US INC | $109.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.33 | 2019 | |
| Pfizer INC. | $28.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.80 | 2019 | |
| Abbott Laboratories | $24.74 | 2019 | |
| Fidia Pharma USA INC. | $18.59 | 2019 | |
| Genentech USA, INC. | $13.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raju Patnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.